Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Hemenway Trust Co LLC

Hemenway Trust Co LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,408 shares of the medical research company’s stock after acquiring an additional 156 shares during the quarter. Hemenway Trust Co LLC’s holdings in Thermo Fisher Scientific were worth $2,813,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $3,149,754,000. Proficio Capital Partners LLC lifted its holdings in Thermo Fisher Scientific by 68,617.0% in the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock worth $396,810,000 after acquiring an additional 761,649 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $377,901,000. Grantham Mayo Van Otterloo & Co. LLC raised its position in shares of Thermo Fisher Scientific by 140.7% during the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company’s stock worth $569,062,000 after purchasing an additional 639,467 shares during the period. Finally, Lindsell Train Ltd bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $211,858,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $437.71 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $437.22 and a 1 year high of $627.88. The stock’s 50-day moving average price is $532.01 and its two-hundred day moving average price is $547.91. The company has a market cap of $165.13 billion, a PE ratio of 26.48, a PEG ratio of 2.99 and a beta of 0.79. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.41%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TMO shares. Bank of America cut their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Scotiabank boosted their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. Raymond James restated an “outperform” rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $653.23.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 over the last three months. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.